| Strategic International Session (Symposium)3(JSGS・JSGE・JGES) |
| Sat. November 7th 9:00 - 11:00 Room 9: Portopia Hotel Main Building Kairaku 3 |
| New strategy for lower advanced rectal cancer: preoperative chemoradiotherapy with UFT/leucovorin/irinotecan regimen | |||
| Shigenobu Emoto1, Kazushige Kawai1, Soichiro Ishihara1 | |||
| 1Department of Surgical Oncology, The University of Tokyo | |||
|
|||
|
|||
| Background: We previously reported that UFT/leucovorin/irinotecan (TEGAFIRI) is a feasible chemotherapy regimen for preoperative chemoradiotherapy (CRT) for lower advanced rectal cancer (LARC) in a phase I/II trial. Here we report the short-term outcomes for further accumulated LARC cases treated with this regimen. Methods: A total of 41 LARC patients were treated with preoperative CRT with TEGAFIRI regimen (irinotecan 80 mg/m2 on day 1, 15, 29, 43, UFT 300 mg/m2 and leucovorin 75 mg/body with irradiation 50.4 Gy/28Fr) followed by curative intent surgery. The relative dose intensity (RDI), adverse events (AEs), surgical findings, and pathological regression grade and complete response (pCR) rate were examined. Results: The mean RDI was 0.86 for irinotecan, 0.97 for UFT, and 0.998 for irradiation. Grade 3 AEs were diarrhea in 5 patients (12.1%), anemia in 4 (9.8%), and leukopenia and neutropenia in 3 (7.3%) respectively, and no grade 4 or 5 AEs were observed. The circumferential resection margin was negative in all cases. The pathological regression grade 1a/1b/2/3 was observed in 4/10/20/7 cases, and the pCR rate was 17.1%. In 26 patients treated with irinotecan at 80 mg/m2, the pCR rate was 19.2% and the grade 2/3 regression was observed in 73.1% of the patients. Conclusions: Preoperative CRT with TEGAFIRI regimen for LARC is considered promising in terms of safety and efficacy. |
|||
|
Index Term 1: colorectal cancer Index Term 2: preoperative chemoradiotherapy |
|||
| Page Top | |||